Aug 13, 2020
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Vosoritide to Treat Children with Achondroplasia
Apr 06, 2020
BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe
Dec 16, 2019
BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide
Nov 14, 2019
Poised for Significant Growth and Profitability, BioMarin Shares Company Highlights During R&D Day on November 14th in New York
Nov 14, 2019
BioMarin Announces Cumulative Additional Height Gain of 9.0 cm over 54 months versus Natural History in Children with Achondroplasia Treated with Vosoritide in Phase 2 Study
Nov 06, 2019
BioMarin to Highlight Innovative Development Pipeline at R&D Day on November 14th
Jun 18, 2019
BioMarin Announces New England Journal of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up to 42 Months in Children with Achondroplasia
Nov 01, 2018
BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on November 7th in New York
Jun 14, 2018
BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia
Apr 25, 2018
BioMarin Announces First Quarter 2018 Financial Results
Oct 18, 2017
BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
Oct 11, 2017
BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
Aug 02, 2017
BioMarin Announces Second Quarter 2017 Financial Results